<DOC>
	<DOC>NCT00538239</DOC>
	<brief_summary>The purpose of this study is to determine whether maintenance therapy with oral AP23573 (ridaforolimus), by preventing and controlling tumor growth for a prolonged period of time in patients with metastatic soft-tissue or bone sarcomas responding to chemotherapy, will result in clinically significant improvement in progression-free survival as compared to oral placebo.</brief_summary>
	<brief_title>Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Confirmed diagnosis of metastatic softtissue or bone sarcoma Ongoing complete response, partial response, or stable disease (RECIST) after a minimum of 4 cycles (and maximum of 12 months) of any one first, second, or third line of prior cytotoxic chemotherapy for metastatic disease Eastern Cooperative Oncology Group performance status of 0 or 1 Adequate organ and bone marrow function Completed prior chemotherapy with last dose received at least 3 and up to 12 weeks prior to randomization Prior therapy with rapamycin or rapamycin analogs Ongoing toxicity associated with prior anticancer therapy Another primary malignancy within the past three years Concomitant medications that induce or inhibit CYP3A Significant, uncontrolled cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>